NO20090262L - Galeniske formuleringer av aliskiren og hydroklorotiazid - Google Patents
Galeniske formuleringer av aliskiren og hydroklorotiazidInfo
- Publication number
- NO20090262L NO20090262L NO20090262A NO20090262A NO20090262L NO 20090262 L NO20090262 L NO 20090262L NO 20090262 A NO20090262 A NO 20090262A NO 20090262 A NO20090262 A NO 20090262A NO 20090262 L NO20090262 L NO 20090262L
- Authority
- NO
- Norway
- Prior art keywords
- aliskiren
- hydrochlorothiazide
- galenic formulations
- combinations
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0612540.5A GB0612540D0 (en) | 2006-06-23 | 2006-06-23 | Galenical formulations of organic compounds |
PCT/EP2007/005476 WO2007147596A1 (en) | 2006-06-23 | 2007-06-21 | Galenical formulations of aliskiren and hydrochlorothiazide |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20090262L true NO20090262L (no) | 2009-01-19 |
Family
ID=36803824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20090262A NO20090262L (no) | 2006-06-23 | 2009-01-16 | Galeniske formuleringer av aliskiren og hydroklorotiazid |
Country Status (26)
Country | Link |
---|---|
US (1) | US8618172B2 (pt) |
EP (3) | EP2311439A1 (pt) |
JP (1) | JP5362556B2 (pt) |
KR (1) | KR101442272B1 (pt) |
CN (1) | CN101472566A (pt) |
AR (1) | AR061565A1 (pt) |
AU (1) | AU2007263261B2 (pt) |
BR (1) | BRPI0713338A2 (pt) |
CA (1) | CA2654872A1 (pt) |
CL (1) | CL2007001837A1 (pt) |
EC (1) | ECSP088986A (pt) |
ES (1) | ES2704979T3 (pt) |
GB (1) | GB0612540D0 (pt) |
GT (1) | GT200800297A (pt) |
IL (1) | IL195425A (pt) |
MA (1) | MA30527B1 (pt) |
MX (1) | MX2008016533A (pt) |
MY (1) | MY146779A (pt) |
NO (1) | NO20090262L (pt) |
NZ (1) | NZ572937A (pt) |
PE (2) | PE20080373A1 (pt) |
RU (1) | RU2491058C2 (pt) |
TN (1) | TNSN08528A1 (pt) |
TW (1) | TWI457137B (pt) |
WO (1) | WO2007147596A1 (pt) |
ZA (1) | ZA200809773B (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI436760B (zh) * | 2007-09-28 | 2014-05-11 | Novartis Ag | 阿利克侖之蓋崙(galenical)調配物 |
EP2143425A1 (de) * | 2008-07-11 | 2010-01-13 | Ratiopharm GmbH | Direktverpresste Aliskiren-Tabletten |
US20100093603A1 (en) * | 2008-07-17 | 2010-04-15 | Kenneth Baker | Use of organic compounds |
ES2365429B1 (es) | 2010-03-05 | 2012-09-06 | Universidad De Castilla De La Mancha | Solucion para dialisis peritoneal |
CN102626391B (zh) * | 2012-04-19 | 2013-07-10 | 海南美兰史克制药有限公司 | 一种阿利克仑氢氯噻嗪药物组合物脂质体固体制剂 |
US9301918B2 (en) * | 2013-03-15 | 2016-04-05 | Mallinckrodt Llc | Abuse deterrent solid dosage form for immediate release with functional score |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
TW442301B (en) * | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
TW506836B (en) * | 1996-06-14 | 2002-10-21 | Janssen Pharmaceutica Nv | Fast-dissolving galanthamine hydrobromide tablet |
GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
US6010719A (en) | 1997-09-16 | 2000-01-04 | Universiteit Gent | Freeze-dried disintegrating tablets |
PE20001302A1 (es) | 1998-11-27 | 2000-11-30 | Hoffmann La Roche | Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida |
US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
IS1935B (is) * | 2002-03-19 | 2004-06-16 | Actavis Group Hf. | Fósínópríl lyfjasamsetning |
KR20050008717A (ko) * | 2002-05-17 | 2005-01-21 | 노파르티스 아게 | 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는약제학적 조성물 |
BG65538B1 (bg) * | 2002-07-05 | 2008-11-28 | "Софарма" Ад | Лекарствена форма на силимарин и метод за нейнотополучаване |
WO2005077418A1 (en) * | 2004-02-17 | 2005-08-25 | Novartis Ag | Combination of renin inhibitor and diuretics |
MY144477A (en) * | 2004-03-17 | 2011-09-30 | Novartis Ag | Galenic formulations of organic compounds |
DE602005025755D1 (de) * | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
WO2006041763A1 (en) * | 2004-10-04 | 2006-04-20 | Novartis Ag | Renin inhibitors for treating transplantation induced diseases |
US8367105B2 (en) * | 2004-11-10 | 2013-02-05 | Teva Pharmaceutical Industries, Ltd. | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
JP2008539250A (ja) * | 2005-04-27 | 2008-11-13 | ノバルティス アクチエンゲゼルシャフト | アテローム性動脈硬化症を処置するための方法 |
CN101291662A (zh) * | 2005-10-21 | 2008-10-22 | 诺瓦提斯公司 | 肾素抑制剂和抗血脂异常剂和/或抗肥胖剂的组合 |
-
2006
- 2006-06-23 GB GBGB0612540.5A patent/GB0612540D0/en not_active Ceased
-
2007
- 2007-06-21 EP EP10191022A patent/EP2311439A1/en not_active Withdrawn
- 2007-06-21 ES ES07785832T patent/ES2704979T3/es active Active
- 2007-06-21 EP EP18177693.1A patent/EP3391878A1/en not_active Withdrawn
- 2007-06-21 AU AU2007263261A patent/AU2007263261B2/en not_active Ceased
- 2007-06-21 CA CA002654872A patent/CA2654872A1/en not_active Abandoned
- 2007-06-21 EP EP07785832.2A patent/EP2034968B1/en active Active
- 2007-06-21 KR KR1020087031081A patent/KR101442272B1/ko not_active IP Right Cessation
- 2007-06-21 BR BRPI0713338-3A patent/BRPI0713338A2/pt not_active IP Right Cessation
- 2007-06-21 RU RU2009101971/15A patent/RU2491058C2/ru not_active IP Right Cessation
- 2007-06-21 JP JP2009515768A patent/JP5362556B2/ja not_active Expired - Fee Related
- 2007-06-21 MX MX2008016533A patent/MX2008016533A/es active IP Right Grant
- 2007-06-21 US US12/304,244 patent/US8618172B2/en active Active
- 2007-06-21 WO PCT/EP2007/005476 patent/WO2007147596A1/en active Application Filing
- 2007-06-21 MY MYPI20084990A patent/MY146779A/en unknown
- 2007-06-21 CN CNA2007800225770A patent/CN101472566A/zh active Pending
- 2007-06-21 NZ NZ572937A patent/NZ572937A/en not_active IP Right Cessation
- 2007-06-21 AR ARP070102734A patent/AR061565A1/es unknown
- 2007-06-22 TW TW096122538A patent/TWI457137B/zh not_active IP Right Cessation
- 2007-06-22 CL CL200701837A patent/CL2007001837A1/es unknown
- 2007-06-22 PE PE2007000804A patent/PE20080373A1/es not_active Application Discontinuation
- 2007-06-22 PE PE2012000368A patent/PE20120990A1/es not_active Application Discontinuation
-
2008
- 2008-11-17 ZA ZA200809773A patent/ZA200809773B/xx unknown
- 2008-11-20 IL IL195425A patent/IL195425A/en not_active IP Right Cessation
- 2008-12-17 GT GT200800297A patent/GT200800297A/es unknown
- 2008-12-17 EC EC2008008986A patent/ECSP088986A/es unknown
- 2008-12-19 TN TNP2008000528A patent/TNSN08528A1/en unknown
- 2008-12-24 MA MA31502A patent/MA30527B1/fr unknown
-
2009
- 2009-01-16 NO NO20090262A patent/NO20090262L/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20090262L (no) | Galeniske formuleringer av aliskiren og hydroklorotiazid | |
WO2008085765A3 (en) | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | |
CL2013001586A1 (es) | Composicion microgranular de rapida dispersion que comprende al menos un alcohol de azucar, un sacarido, o una mezcla de estos, al menos un super disgregante y al menos un aditivo multifuncion; comprimido de desintegracion oral que comprende la composicion microgranular y al menos un principio activo; y metodos de fabricacion. | |
WO2008069921A3 (en) | Oral transmucosal nicotine dosage form | |
NO20090141L (no) | Stabiliserte, farmasøytiske preparater som omfatter fesoterodin | |
IL192740A (en) | Use of Sphingomyelinic Acid Pharmaceuticals for the Preparation of Medication Adapted to the Neymen-Pick A or B Disease Rooms | |
JP2010047612A5 (pt) | ||
BRPI0821004A8 (pt) | Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste | |
MX2010003923A (es) | Formulacion farmaceutica de valsartan. | |
WO2011110939A3 (en) | Pharmaceutical compositions of substituted benzhydrylpiperazines | |
IL195269A0 (en) | Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic | |
WO2010038237A3 (en) | Compositions exhibiting delayed transit through the gastrointestinal tract | |
JP2009531457A5 (pt) | ||
ECSP10010052A (es) | Formulaciones galenicas de alisquireno y valsartan | |
MX2010006284A (es) | Formulaciones farmaceuticas de fenilefrina y composiciones para la absorcion transmucosal. | |
NO20082047L (no) | Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme | |
EP2142549A4 (en) | ADENOSINE DERIVATIVES, METHODS OF THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES THEREOF CONTAINING THEM AS AN ACTIVE SUBSTANCE | |
NO20074933L (no) | Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat | |
WO2010046933A3 (en) | Pharmaceutical compositions of taste-masked linezolid | |
DK1994926T3 (da) | Valsartanformuleringer | |
WO2007011958A3 (en) | Intraoral dosage forms of glucagon | |
IT1401284B1 (it) | Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system). | |
WO2008075984A3 (en) | Tablet formulation including macrocyclic lactone and levamisole anthelmintic agents | |
WO2009086077A3 (en) | A1 adenosine receptor antagonists | |
WO2007116297A3 (en) | Use of aminapthone for the preparation of a medicament for treating arteriophaties |